Neural tube closure defect

Neural tube closure defects (NTDs), also known as neural tube defects, are a group of congenital malformations that occur when the neural tube fails to close properly during early embryonic development, typically between the 3rd and 4th weeks of gestation. The neural tube is the embryonic structure that gives rise to the brain and spinal cord. Failure of closure at different points along the neural tube results in a spectrum of conditions, including anencephaly (failure of cranial closure, incompatible with life), spina bifida (incomplete closure of the spinal column, ranging from spina bifida occulta to myelomeningocele), encephalocele (protrusion of brain tissue through a skull defect), and craniorachischisis (failure of the entire neural tube to close). These defects primarily affect the central nervous system but can have widespread consequences on multiple body systems including the musculoskeletal, urinary, and gastrointestinal systems. Clinical features vary widely depending on the type and severity of the defect. Spina bifida, the most common survivable form, can cause lower limb paralysis or weakness, bowel and bladder dysfunction, hydrocephalus, and Chiari II malformation. Anencephaly is uniformly fatal, typically within hours to days after birth. Encephaloceles may cause intellectual disability, seizures, and visual impairment depending on the location and amount of brain tissue involved. Diagnosis is often possible prenatally through maternal serum alpha-fetoprotein screening and fetal ultrasound. The etiology of neural tube closure defects is multifactorial, involving both genetic susceptibility and environmental factors. Folate (folic acid) deficiency is a well-established risk factor, and periconceptional folic acid supplementation has been shown to significantly reduce the incidence of NTDs. Treatment depends on the specific defect and may include surgical repair (either prenatal or postnatal for myelomeningocele), ventriculoperitoneal shunting for hydrocephalus, and multidisciplinary management of associated complications including orthopedic, urological, and rehabilitative care. Ongoing research continues to explore the genetic architecture underlying NTDs, with variants in folate metabolism genes (such as MTHFR) and planar cell polarity pathway genes implicated in susceptibility.

Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly

Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest

Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)

Source: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months

Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC

Common questions about Neural tube closure defect